China SXT Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2018 | FY2017 |
|---|---|---|
| Revenue | $7.0M | $4.9M |
| Cost of Revenue | $3.6M | $2.6M |
| Gross Profit | $3.4M | $2.3M |
| Gross Margin | 48.5% | 47.4% |
| Operating Expenses | ||
| Research & Development | — | — |
| SG&A Expense | $1.3M | $565.5K |
| Operating Income | $1.6M | $1.6M |
| Operating Margin | 23.3% | 32.8% |
| Interest Expense | $779 | $40.4K |
| Pretax Income | $1.6M | $1.6M |
| Income Tax Expense | $440.1K | $395.0K |
| Net Income | $1.2M | $1.2M |
| Net Margin | 16.9% | 24.3% |
| EPS (Basic) | $0.00 | $0.00 |
| EPS (Diluted) | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 1.56B | 1.56B |
| Shares Outstanding (Diluted) | 1.56B | 1.56B |
| Dividends Per Share | — | — |